Ontology highlight
ABSTRACT:
SUBMITTER: Miyo M
PROVIDER: S-EPMC7376863 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Miyo Masaaki M Kato Takeshi T Yoshino Takayuki T Yamanaka Takeharu T Bando Hideaki H Satake Hironaga H Yamazaki Kentaro K Taniguchi Hiroya H Oki Eiji E Kotaka Masahito M Oba Koji K Miyata Yoshinori Y Muro Kei K Komatsu Yoshito Y Baba Hideo H Tsuji Akihito A
BMC cancer 20200723 1
<h4>Background</h4>First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m<sup>2</sup>), irinotecan (IRI: 200 mg/m<sup>2</sup>), and BEV (7.5 mg/m<sup>2</sup>)] was non-inferior to FOLFIRI+BEV as a second-line ...[more]